Encompass Health Co. (NYSE:EHC - Free Report) - Equities researchers at William Blair reduced their Q2 2024 earnings estimates for Encompass Health in a research report issued on Wednesday, April 24th. William Blair analyst J. Haase now expects that the company will post earnings of $0.96 per share for the quarter, down from their prior estimate of $0.97. William Blair has a "Outperform" rating on the stock. The consensus estimate for Encompass Health's current full-year earnings is $3.96 per share. William Blair also issued estimates for Encompass Health's Q3 2024 earnings at $0.94 EPS, Q4 2024 earnings at $0.99 EPS, FY2024 earnings at $4.01 EPS, Q3 2025 earnings at $1.07 EPS, Q4 2025 earnings at $1.13 EPS and FY2025 earnings at $4.58 EPS.
Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.48%. The company had revenue of $1.32 billion during the quarter, compared to analysts' expectations of $1.27 billion. During the same quarter in the previous year, the company earned $0.88 earnings per share. The firm's revenue for the quarter was up 13.4% on a year-over-year basis.
EHC has been the subject of a number of other research reports. Raymond James reissued a "strong-buy" rating and set a $95.00 target price (up previously from $85.00) on shares of Encompass Health in a research note on Friday. Mizuho boosted their target price on shares of Encompass Health from $93.00 to $95.00 and gave the stock a "buy" rating in a research note on Thursday. Truist Financial boosted their price target on shares of Encompass Health from $82.00 to $86.00 and gave the stock a "buy" rating in a research report on Friday, February 9th. Stephens restated an "overweight" rating and set a $85.00 price target on shares of Encompass Health in a research report on Tuesday, January 16th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $83.00 price target on shares of Encompass Health in a research report on Friday, February 9th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $86.56.
Check Out Our Latest Report on Encompass Health
Encompass Health Stock Performance
EHC traded down $0.27 on Friday, reaching $82.46. The stock had a trading volume of 706,619 shares, compared to its average volume of 672,948. Encompass Health has a 12-month low of $57.55 and a 12-month high of $85.84. The company has a current ratio of 1.28, a quick ratio of 1.28 and a debt-to-equity ratio of 1.19. The business's 50-day moving average price is $78.07 and its two-hundred day moving average price is $70.76. The company has a market cap of $8.26 billion, a P/E ratio of 22.29, a price-to-earnings-growth ratio of 1.53 and a beta of 0.94.
Institutional Investors Weigh In On Encompass Health
A number of institutional investors and hedge funds have recently made changes to their positions in EHC. AE Wealth Management LLC raised its stake in shares of Encompass Health by 26.8% in the 3rd quarter. AE Wealth Management LLC now owns 6,381 shares of the company's stock valued at $429,000 after acquiring an additional 1,350 shares during the period. Oak Thistle LLC purchased a new stake in Encompass Health during the 3rd quarter worth approximately $814,000. Linden Thomas Advisory Services LLC increased its stake in Encompass Health by 22.1% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 15,220 shares of the company's stock worth $1,022,000 after buying an additional 2,754 shares during the period. Copeland Capital Management LLC increased its stake in Encompass Health by 0.5% during the 3rd quarter. Copeland Capital Management LLC now owns 1,277,690 shares of the company's stock worth $85,810,000 after buying an additional 6,009 shares during the period. Finally, Tectonic Advisors LLC purchased a new stake in Encompass Health during the 3rd quarter worth approximately $343,000. 97.25% of the stock is owned by hedge funds and other institutional investors.
Encompass Health Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date was Thursday, March 28th. Encompass Health's dividend payout ratio (DPR) is 16.22%.
Encompass Health Company Profile
(
Get Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Read More
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
